The Thailand Sciences Research and Innovation Fund has backed a breakthrough preclinical study showing that a common plant compound may shield cancer patients from one of chemotherapy's most dangerous side effects—heart damage. The research, published July 1 and conducted at University of Phayao, identifies apigenin, a flavonoid abundant in parsley, celery, chamomile, and citrus fruits, as a potential cardioprotective agent during cancer treatment.
Why This Matters:
• Chemotherapy-induced heart damage affects thousands of cancer survivors in Thailand annually, limiting treatment options and reducing long-term survival.
• Apigenin is readily available in common foods and supplements, making it an accessible intervention if human trials succeed.
• No human trials yet exist, but the preclinical data is robust enough to warrant attention from oncologists and patients navigating treatment decisions.
• Thailand's medical research ecosystem is actively positioning itself in natural compound therapeutics, with implications for regional pharmaceutical development.
Understanding the Heart Risk Hidden in Cancer Treatment
Cisplatin, one of the most widely prescribed chemotherapy agents for lung, ovarian, testicular, and bladder cancers, carries a well-documented cardiovascular toll. The drug triggers oxidative stress, inflammation, and apoptosis (programmed cell death) in cardiac tissue, leading to left ventricular dysfunction—the heart's pumping chamber weakens, sometimes irreversibly.
In Thailand, where cancer incidence has climbed 18% over the past decade according to the Thailand National Cancer Institute, the balancing act between curing cancer and preserving heart function has become a critical clinical challenge. Oncologists routinely face patients whose heart damage from prior chemotherapy limits their eligibility for potentially life-saving subsequent treatments.
The University of Phayao study, funded through Fundamental Fund 2025 (Grant No. 5087/2567), used male Sprague Dawley rats to model cisplatin-induced cardiotoxicity. Researchers administered 50 mg/kg per day of apigenin before cisplatin treatment, then measured a comprehensive panel of cardiac markers.
What the Researchers Found
The results were striking across multiple biological pathways. Rats pretreated with apigenin showed significant improvements in left ventricular function compared to those receiving cisplatin alone. Cardiac injury markers—LDH (lactate dehydrogenase) and CK-MB (creatine kinase-MB), both enzymes released when heart muscle is damaged—dropped substantially in the apigenin group.
Beyond structural protection, the compound demonstrated anti-inflammatory effects. Levels of TNF-α (tumor necrosis factor-alpha) and IL-1β (interleukin-1 beta), key inflammatory cytokines, declined markedly. The study also documented reduced expression of p-NF-κB and TLR-4, proteins that amplify inflammatory cascades in damaged tissue.
At the molecular level, apigenin appeared to work through the CD38-Sirt3 signaling pathway. Cisplatin typically increases cardiac CD38, an enzyme that depletes NAD+ (a crucial cellular energy molecule), while simultaneously decreasing Sirt3 and SOD2 (superoxide dismutase 2), proteins essential for mitochondrial health and antioxidant defense. Apigenin pretreatment reversed these changes, suggesting it helps restore the heart's cellular energy balance and oxidative defense systems.
The compound also inhibited apoptosis by favorably modulating the Bax/Bcl-2 ratio and reducing cleaved caspase-3, a key executioner of cell death programs.
The Apigenin Advantage: More Than Just an Antioxidant
Apigenin belongs to the flavonoid family, plant compounds that give fruits and vegetables their color and have been studied extensively for health benefits. Unlike many experimental drugs, apigenin is already present in the human diet—parsley contains up to 225 mg per 100 grams, while celery and chamomile tea offer moderate amounts.
Previous international research has shown apigenin's protective effects against doxorubicin, another cardiotoxic chemotherapy drug. Studies documented how the compound reduces cardiac fibrosis (scarring), prevents cardiomyocyte apoptosis through the PI3K/AKT/mTOR pathway, and inhibits pathological cardiac hypertrophy (thickening of heart muscle).
What makes apigenin particularly intriguing is its dual action: it may enhance the cancer-killing effects of chemotherapy while simultaneously protecting healthy tissue. Laboratory studies have shown synergistic anticancer activity when apigenin is combined with conventional chemotherapy agents, meaning lower chemotherapy doses might achieve the same tumor control—a scenario that could reduce overall toxicity.
What This Means for Cancer Patients in Thailand
This research remains firmly in the preclinical stage. No human trials of apigenin for chemotherapy-related cardiotoxicity have been conducted in Thailand or published elsewhere as of July 2026. The rat dosage of 50 mg/kg would translate to approximately 3,500 mg daily for a 70-kilogram human—far exceeding what could be obtained through diet alone and requiring pharmaceutical-grade supplementation.
Patients currently undergoing chemotherapy should not self-prescribe apigenin supplements without oncologist consultation. Natural compounds can interact with chemotherapy drugs, potentially altering their metabolism and effectiveness. The Thailand Food and Drug Administration has not approved apigenin as a cardioprotective agent, and no standardized dosing protocols exist.
However, the research does open a pathway for future clinical investigation. Thailand's medical research infrastructure, particularly at University of Phayao, Mahidol University, and Chulalongkorn University, has been actively studying natural compounds for cancer-related applications. Researchers at Mahidol's Institute of Molecular Biosciences have explored similar approaches using moringa pod extracts and brown algae, while Khon Kaen University scientists have investigated indigenous herbs with anticancer properties—though none have yet progressed to human trials.
The funding through Thailand Sciences Research and Innovation Fund signals government-level interest in positioning Thailand as a regional hub for natural compound therapeutics, potentially creating a competitive advantage in the growing integrative oncology market.
The Long Road from Laboratory to Clinic
Translating this rat study into human medicine requires multiple steps, each consuming years and substantial resources. Phase I safety trials would need to establish the maximum tolerated dose in healthy volunteers. Phase II would test efficacy in cancer patients receiving cisplatin, measuring cardiac function through echocardiography and biomarker analysis. Phase III would require hundreds of patients across multiple sites to prove apigenin reduces clinically meaningful cardiac events.
This process typically takes 7-10 years and costs millions of dollars. In Thailand, researchers face additional hurdles securing international pharmaceutical partnerships and navigating regulatory pathways for novel therapeutics derived from natural sources.
Yet the potential payoff is substantial. Cardiotoxicity limits treatment options for an estimated 20-30% of cancer survivors in developed healthcare systems, a figure likely higher in Thailand where baseline cardiovascular disease prevalence is elevated. An effective cardioprotective agent could expand chemotherapy eligibility, improve cancer survival rates, and reduce long-term healthcare costs from heart failure.
For now, the research serves as proof of concept—another piece of evidence that the intersection of traditional plant-based medicine and modern pharmaceutical science may yield practical clinical tools. Thailand's growing research capacity in this space suggests more discoveries may follow as the nation's scientists systematically investigate the therapeutic potential hidden in common foods and herbs.
